Corporate Profile

La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.

Featured Documents

06/16/18A Phase 1, Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of LJPC-401
06/16/18EHA Poster
12/22/17GIAPREZA™ (angiotensin II) Update

Share Price

Stock chart for: LJPC.OQ.  Currently trading at $5.93 with a 52 week high of $38.39 and a 52 week low of $5.01.
Price$5.93
Change (%) Stock is Up 0.09 (0.00%)
Volume162,048
Data as of 02/21/19 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.


Upcoming Events




There are currently no events scheduled.

Recent News


La Jolla Pharmaceutical Company Announces Data Presentations at the Society of Critical Care Medicine’s 48th Critical Care Congress

02/14/19

New Data on GIAPREZA™ (angiotensin II) to be Presented in Oral Sessions at the Society of Critical Care Medicine’s 48th Critical Care Congress SAN DIEGO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announ

Read More

La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives

01/07/19

- Fourth-Quarter 2018 Net Sales of GIAPREZA Were Approximately $4.2 Million, Up 20% from the Third Quarter of 2018 - - Full-Year 2019 Net Sales Guidance for GIAPREZA of $24 Million to $28 Million - - Decision on GIAPREZA MAA by EMA Expected in Ju

Read More

La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference

01/04/19

SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More



Print Page Print PageE-mail Page E-mail PageRSS Feeds RSS FeedsE-mail Alerts E-mail AlertsIR Contacts IR Contacts